摘要
Ovarian cancer (OV) is the most lethal gynecological malignancy and requires improved early detection methods and more effective intervention to achieve a better prognosis. The lack of sensitive and noninvasive biomarkers with clinical utility remains a challenge. Here, we conducted a genome-wide copy number variation (CNV) profil -ing analysis using low-coverage whole genome sequencing (LC-WGS) of plasma cfDNA in patients with nonmalig-nant and malignant ovarian tumors and identified 10 malignancy-specific and 12 late-stage-specific CNV markers from plasma cfDNA LC-WGS data. Concordance analysis indicated a significant correlation of identified CNV markers between CNV profiles of plasma cfDNA and tissue DNA (Pearson's r = 0.64, P = 0.006 for the TCGA cohort and r = 0.51, P = 0.04 for the Dariush cohort). By leveraging these specific CNV markers and machine learning algorithms, we developed robust predictive models showing excellent performance in distinguishing between malignant and nonmalignant ovarian tumors with F1-scores of 0.90 and ranging from 0.75 to 0.99, and prediction accuracy of 0.89 and ranging from 0.66 to 0.98, respectively, as well as between early-and late-stage ovarian tumors with F1-scores of 0.84 and ranging from 0.61 to 1.00, and prediction accuracy of 0.82 and ranging from 0.63 to 0.96 in our institute cohort and other external validation cohorts. Furthermore, we also discovered and validated certain CNV features associated with survival outcomes and platinum-based chemotherapy response in multicenter cohorts. In conclusion, our study demonstrated the clinical utility of CNV profiling in plasma cfDNA using LC-WGS as a cost-effective and accessible liquid biopsy for OV.
学科与关键词
- Personalized Ovarian Cancer Disease Surveillance and Detection of Candidate Therapeutic Drug Target in Circulating Tumor DNAJohn A. Martignetti; Olga Camacho-Vanegas; Nolan Priedigkeit; Catalina Camacho; Elena Pereira; Li Lin; Leopold Garnar-Wortzel; Dagny Miller; Bojan Losic; Hardik Shah; Jun Liao; Jian Ma; Pratik Lahiri; Mark Chee; Eric Schadt; Peter DottinoNeoplasia, 2014, 16(1): 97-w29.被引 42
- Personalized ovarian cancer surveillance and detection of a therapeutic drug target in circulating tumor DNAMartignetti, John A.; Camacho-Vanegas, Olga; Priedigkeit, Nolan; Camacho-Vanegas, Catalina; Pereira, Elena; Lin, Li; Losic, Bojan; Shah, Hardik; Liao, Jun; Ma, Jian; Lahiri, Pratik; Chee, Mark; Schadt, Eric; Dottino, Peter105th Annual Meeting of the American-Association-for-Cancer-Research (AACR), San Diego, CA, 2014-04-05 To 2014-04-09.
- The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers for diagnosis and prognosis stratification of pancreatic ductal adenocarcinomaWang, Y.; Jiang, R.; Xiao, S.; Shi, Y.; Zheng, J.; Li, Z.; Peng, J.; Sun, J.; Yang, G.; Yuan, J.; Lou, W.23rd ESMO World Congress on Gastrointestinal Cance, ELECTR NETWORK, 2021-06-30 To 2021.
